静脉活性化合物在血栓形成后综合征中的实用性:系统性审查
Monika L Gloviczki1, Julianne Stoughton2, Alessandra Puggioni3
1Department of Internal Medicine and Gonda Vascular Center, Mayo Clinic, Rochester, MN; VASA LLC, Scottsdale, AZ.
Journal of vascular surgery. Venous and lymphatic disorders
|March 18, 2025
概括
静脉活性化合物 (VACs) 显示了适度的证据,改善症状,减少,并治愈后血栓综合征 (PTS) 的. 更高质量的研究表明,VAC可能有助于预防PTS,当与Rivaroxaban一起使用时.
科学领域:
- 血管医学 血管医学
- 药理学 药理学是指药理学的学科.
- 基于证据的医学基于证据的医学.
背景情况:
- 血栓后综合征 (PTS) 是下肢深静脉血栓症 (DVT) 后的一个常见并发症,影响超过50%的患者.
- 从历史上看,静脉活性化合物 (VAC) 已被推用于慢性静脉功能不全,包括PTS管理.
研究的目的:
- 系统地审查和评估有关VACs在PTS预防和治疗中的有效性证据的质量.
- 评估目前关于VACs在管理与PTS相关的症状和结果方面的文献.
主要方法:
- 从1980年到2023年,在主要数据库 (PubMed,MEDLINE,Cochrane图书馆) 进行了系统的文献搜索.
- 仅包括遵守PRISMA指南的英语随机对照试验 (RCT).
- 使用修订后的Cochrane工具评估偏差风险.
主要成果:
- 十一项RCT满足了纳入标准,评估了迪奥斯,水胺/鲁化物,微化纯化黄素分数 (MPFF) 和硫氧化物.
- 研究表明,VACs改善了静脉症状,减少了,并促进了PTS患者的愈.
- 两项试点RCT表明,作为Rivaroxaban的辅助剂,迪奥斯和MPFF可以预防PTS并改善深静脉再通道,偏差风险低.
结论:
- 在PTS中,VAC至少有适度的证据表明可以改善静脉症状,减少,并治愈.
- 新出现的证据表明,特定的VACs (迪奥司明,MPFF) 在与抗凝药结合时,在PTS预防方面具有潜在的益处.
- 由于现有研究的局限性,需要进一步的高质量,低偏差的RCT来最终确定VACs在PTS预防和治疗中的作用.
相关概念视频
Venous Return
3.5K
The circulatory system plays a crucial role in ensuring the optimal functioning of the human body. One of its critical components is venous return - the process that completes the blood circulation cycle. This article will delve into the concept of venous return, how it works, and its significance to our health.
What is Venous Return?
Venous return refers to the rate at which blood flows back to the heart from the body's peripheral veins. It's an integral part of the circulatory system...
What is Venous Return?
Venous return refers to the rate at which blood flows back to the heart from the body's peripheral veins. It's an integral part of the circulatory system...
3.5K
Anticoagulant Drugs: Low-Molecular-Weight Heparins
654
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
654
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
Vascular Spasm
1.3K
The vascular phase, also known as vasospasm, is the initial stage of hemostasis, crucial for preventing excessive bleeding when a blood vessel is injured. After a vessel is cut, nerves in the damaged area trigger pain and other sensory impulses. Simultaneously, the smooth muscles in the vessel wall contract, resulting in a vascular spasm. This contraction reduces the vessel's diameter at the injury site, slowing or stopping blood loss through the vessel wall. Vascular spasms typically last...
1.3K
Clot Retraction and Fibrinolysis
5.0K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
5.0K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
501
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
501


